BACKGROUND AND OBJECTIVES: To date, very few cases with adult-onset focal segmental glomerulosclerosis (FSGS) carrying NPHS2 variants have been described, all of them being compound heterozygous for the p.R229Q variant and one pathogenic mutation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Mutation analysis was performed in 148 unrelated Spanish patients, of whom 50 presented with FSGS after 18 years of age. Pathogenicity of amino acid substitutions was evaluated through an in silico scoring system. Haplotype analysis was carried out using NPHS2 single nucleotide polymorphism and microsatellite markers. RESULTS: Compound heterozygous or homozygous NPHS2 pathogenic mutations were identified in seven childhood-onset steroid-resistant nephrotic syndrome (SRNS) cases. Six additional cases with late childhood- and adult-onset SRNS were compound heterozygotes for p.R229Q and one pathogenic mutation, mostly p.A284V. p.R229Q was more frequent among SRNS cases relative to controls (odds ratio=2.65; P=0.02). Significantly higher age at onset of the disease and slower progression to ESRD were found in patients with one pathogenic mutation plus the p.R229Q variant in respect to patients with two NPHS2 pathogenic mutations. CONCLUSIONS: NPHS2 analysis has a clinical value in both childhood- and adult-onset SRNS patients. For adult-onset patients, the first step should be screening for p.R229Q and, if positive, for p.A284V. These alleles are present in conserved haplotypes, suggesting a common origin for these substitutions. Patients carrying this specific NPHS2 allele combination did not respond to corticoids or immunosuppressors and showed FSGS, average 8-year progression to ESRD, and low risk for recurrence of FSGS after kidney transplant.
BACKGROUND AND OBJECTIVES: To date, very few cases with adult-onset focal segmental glomerulosclerosis (FSGS) carrying NPHS2 variants have been described, all of them being compound heterozygous for the p.R229Q variant and one pathogenic mutation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Mutation analysis was performed in 148 unrelated Spanish patients, of whom 50 presented with FSGS after 18 years of age. Pathogenicity of amino acid substitutions was evaluated through an in silico scoring system. Haplotype analysis was carried out using NPHS2 single nucleotide polymorphism and microsatellite markers. RESULTS: Compound heterozygous or homozygous NPHS2 pathogenic mutations were identified in seven childhood-onset steroid-resistant nephrotic syndrome (SRNS) cases. Six additional cases with late childhood- and adult-onset SRNS were compound heterozygotes for p.R229Q and one pathogenic mutation, mostly p.A284V. p.R229Q was more frequent among SRNS cases relative to controls (odds ratio=2.65; P=0.02). Significantly higher age at onset of the disease and slower progression to ESRD were found in patients with one pathogenic mutation plus the p.R229Q variant in respect to patients with two NPHS2 pathogenic mutations. CONCLUSIONS:NPHS2 analysis has a clinical value in both childhood- and adult-onset SRNS patients. For adult-onset patients, the first step should be screening for p.R229Q and, if positive, for p.A284V. These alleles are present in conserved haplotypes, suggesting a common origin for these substitutions. Patients carrying this specific NPHS2 allele combination did not respond to corticoids or immunosuppressors and showed FSGS, average 8-year progression to ESRD, and low risk for recurrence of FSGS after kidney transplant.
Authors: M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins Journal: Bioinformatics Date: 2007-09-10 Impact factor: 6.937
Authors: Eduardo J B Monteiro; Alexandre C Pereira; Aparecido B Pereira; José E Krieger; Gianna Mastroianni-Kirsztajn Journal: J Nephrol Date: 2006 May-Jun Impact factor: 3.902
Authors: Bernward G Hinkes; Bettina Mucha; Christopher N Vlangos; Rasheed Gbadegesin; Jinhong Liu; Katrin Hasselbacher; Daniela Hangan; Fatih Ozaltin; Martin Zenker; Friedhelm Hildebrandt Journal: Pediatrics Date: 2007-03-19 Impact factor: 7.124
Authors: Louise M McKenzie; Sher L Hendrickson; William A Briggs; Richard A Dart; Stephen M Korbet; Michelle H Mokrzycki; Paul L Kimmel; Tejinder S Ahuja; Jeffrey S Berns; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; Monique Cho; Yu C Zhou; Elizabeth Binns-Roemer; Gregory D Kirk; Jeffrey B Kopp; Cheryl A Winkler Journal: J Am Soc Nephrol Date: 2007-10-17 Impact factor: 10.121
Authors: Sandro Rossetti; Mark B Consugar; Arlene B Chapman; Vicente E Torres; Lisa M Guay-Woodford; Jared J Grantham; William M Bennett; Catherine M Meyers; Denise L Walker; Kyongtae Bae; Qin Jean Zhang; Paul A Thompson; J Philip Miller; Peter C Harris Journal: J Am Soc Nephrol Date: 2007-06-20 Impact factor: 10.121
Authors: Ning He; Alireza Zahirieh; Yan Mei; Brian Lee; Sean Senthilnathan; Betty Wong; Bettina Mucha; Friedhelm Hildebrandt; David E Cole; Daniel Cattran; York Pei Journal: Clin J Am Soc Nephrol Date: 2006-10-25 Impact factor: 8.237
Authors: Jürgen Floege; Robert H Mak; Bruce A Molitoris; Giuseppe Remuzzi; Pierre Ronco Journal: Nat Rev Nephrol Date: 2015-09-29 Impact factor: 28.314
Authors: Agnieszka Bińczak-Kuleta; Jacek Rubik; Mieczysław Litwin; Małgorzata Ryder; Klaudyna Lewandowska; Olga Taryma-Leśniak; Jeremy S Clark; Ryszard Grenda; Andrzej Ciechanowicz Journal: Bosn J Basic Med Sci Date: 2014-05 Impact factor: 3.363
Authors: Maija Suvanto; Jaakko Patrakka; Timo Jahnukainen; Pia-Maria Sjöström; Matti Nuutinen; Pekka Arikoski; Janne Kataja; Marjo Kestilä; Hannu Jalanko Journal: Clin Exp Nephrol Date: 2016-08-29 Impact factor: 2.801